ArticleBiomolecules & biomedicine2025
Decitabine suppresses tumor growth by activating mouse mammary tumor virus and interferon-β pathways.
Article in Biomolecules & biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Endogenous retroviruses and response to immune checkpoint inhibitors: mechanisms, clinical evidence, and therapeutic implications.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Decitabine (DAC), a DNA methyltransferase inhibitor (DNMTi), is clinically effective in hematological malignancies such as myelodysplastic syndrome and acute myeloid leukemia, but its precise antineoplastic mechanisms remain incompletely understood. Beyond promoter demethylation, DAC is known to activate endogenous retroviruses (ERVs) and trigger type I interferon (IFN-I) responses, a phenomenon known as viral mimicry. The aim of this study was to investigate the roles of the mouse mammary tumor virus (MMTV) and interferon-β (IFN-β) in DAC-mediated tumor suppression. We employed two murine tumor models-4T1 mammary carcinoma and MC38 colon adenocarcinoma-in syngeneic immunocompetent mice, immunodeficient nude mice, and in vitro cultures. RNA and protein expression were assessed by quantitative PCR and immunoblotting, while functional contributions of MMTV and IFN-β were tested using short hairpin RNA (shRNA) knockdowns. DAC treatment suppressed tumor growth and pulmonary metastasis in vivo and inhibited cancer cell proliferation in vitro. It induced transcription of MMTV and expression of IFN-β, with a strong negative correlation between MMTV Env protein levels and tumor mass. Knockdown of either MMTV or IFN-β conferred resistance to DAC, confirming their functional roles. Reciprocal regulation was observed: MMTV knockdown reduced IFN-β expression, while IFN-β knockdown increased MMTV Env accumulation. Furthermore, DAC upregulated interferon regulatory factor 7 (IRF7), but this effect declined during prolonged treatment, suggesting a temporally restricted therapeutic window. In conclusion, our findings provide in vivo support for the viral mimicry hypothesis and demonstrate that MMTV and IFN-β contribute to DAC-mediated tumor suppression. The observed IRF7 downregulation and potential induction of immune checkpoints highlight the importance of therapeutic strategies combining DNMTis with immune checkpoint blockade to sustain antineoplastic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.